PIK3CA and colorectal cancer: The current study demonstrates the feasibility of developing novel tumor models with CSC properties to reveal the anticancer activity of a novel dual PI3K/mTOR inhibitor in colorectal cancers harboring a specific hotspot mutation, highlighting the importance of performing pharmacological studies using a genetically characterized CSC model.